Business Model Breakdown
How Jazz Pharmaceuticals PLC Makes Money
JAZZ
Market Cap
$11.9B
Annual Revenue
$4.2B
Profit Margin
-8.3%
Employees
2,800
The Short Version
Jazz Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing innovative medicines for people with serious diseases, often with limited or no therapeutic options. It generates revenue primarily by selling its pharmaceutical products, which target areas like sleep disorders (e.g., narcolepsy, idiopathic hypersomnia) and oncology (e.g., certain types of cancer). The company invests significantly in research and development to discover and advance new drug candidates, then commercializes them through its sales and marketing teams to healthcare providers globally.
Where the Revenue Comes From
Xywav sales (~38% of 2025 revenue, based on $465M Q4 out of $1.20B)
Epidiolex/Epidyolex sales
Zanidatamab sales (pending launch)
Other oncology products (e.g., Zepzelca, Rylaze, Modeyso)
Who buys: Primarily patients suffering from sleep disorders (narcolepsy, idiopathic hypersomnia), various forms of epilepsy, and specific cancers, accessed via prescriptions from physicians and specialists.
Why It Works (Competitive Advantages)
- ✔Patented drug portfolio (Xywav, Epidiolex, zanidatamab pending)
- ✔Established commercial infrastructure in neuroscience and oncology
- ✔Strong cash flow generation for R&D and M&A
Economic Moat: Narrow (Intangible Assets/IP (patent protection for key drugs), Switching Costs (for patients on chronic treatments like sleep disorders and epilepsy))
What Our Analysis Says
DVR Score as of April 14, 2026
Jazz Pharmaceuticals remains a well-established biopharmaceutical company with strong execution on its neuroscience and oncology portfolio. The Q4 2025 earnings beat, 10% YoY revenue growth, and 16% YoY Xywav revenue growth demonstrate stable performance. The advancement of zanidatamab (HER2+ GEA) with breakthrough designation and potential H2 2026 approval provides a significant near-term catalyst and growth driver, moving beyond incremental label expansions. Profitability remains robust with improving operating margins and substantial free cash flow generation ($1.30B in FY2025, 35% FCF margin forecast 2026). However, despite these positives, at a $12.02B market cap, the company fundamentally lacks the disruptive technology or entry into entirely new, massive markets required for a 10x return within a 3-5 year timeframe. Its growth will likely be steady and incremental, driven by pipeline success and lifecycle management, rather than exponential.